2 results
Approved WMOCompleted
Primary Objective- To demonstrate dose proportionality between 1 mg and 5 mg of PedPRM (Neurim Pharmaceuticals Ltd.) following a single oral dose in healthy male and female volunteers (treatment A and C), under fed conditions.Secondary Objectives-…
Approved WMOCompleted
To investigate whether discontinuation of Syntocinon® infusion after the onset of active labour decreases caesarean section rates compared to usual care; continuation of oxytocin until the baby and placenta is born.